# IAP6 Rec'd PCT/PTO 31 AUG 2006

Attorney's Docket No.: 07039-409US1 / MMV-02-036



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shuchong Pan et al.

Serial No.: 10/561,014

Filed: December 16, 2005

Art Unit: 1649

Examiner: Unknown

Conf. No.: 9426

Title : ISOFORMS OF BRAIN NATRIURETIC PEPTIDE

## Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **TRANSMITTAL**

The following correspondence relating to this application is enclosed for filing:

- 1. Information Disclosure Statement (1 page);
- 2. Form PTO-1449 (2 pages);
- 3. Copies of Cited References (25 references); and
- 4. A Return Postcard.

Please date stamp and return the enclosed postcard. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: Hugust 25, 2006

J. Patrick Finn III, Ph.D. Reg. No. 44,109

Fish & Richardson P.C. 60 South Sixth Street Suite 3300 Minneapolis, MN 55402 (612) 335, 5070 telephone

(612) 335-5070 telephone

(612) 288-9696 facsimile

60375383.doc

### CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

Signature

Lisa M. Becker

Typed or Printed Name of Person Signing Certificate



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shuchong Pan et al.

Serial No.: 10/561,014

Filed: December 16, 2005

Art Unit: 1649

Examiner: Unknown

Conf. No.: 9426

Title : ISOFORMS OF BRAIN NATRIURETIC PEPTIDE

#### MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: August 25, 2006

J. Patrick Finn III, Ph.D.

Reg. No. 44,109

Fish & Richardson P.C. 60 South Sixth Street, Suite 3300 Minneapolis, MN 55402 Telephone: (612) 335-5070

Facsimile: (612) 288-9696

60375124.doc

#### CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

August 21, 2000

Date of Deposit

Signature

Lisa M. Becker

Typed or Printed Name of Person Signing Certificate

L	Substitute Form F	PTO-1449
10	4) Info	rmation
ALIG S	1 2006	b

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 07039-409US1

Application No. 10/561,014

ation Disclosure Statement by Applicant (Use several sheets if necessary)

Applicant Shuchong Pan et al.

Filing Date

Group Art Unit 1649

December 16, 2005

			U.S. Pate	ent Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,034,074	07/05/77	Miles			
	2	4,098,876	07/04/78	Piasio et al.			
	3	4,233,402	11/11/80	Maggio et al.			
	4	4,996,143	02/26/91	Heller et al.			
	5	5,114,923	05/19/92	Seilhamer et al.			
_	6	5,296,347	03/22/94	LaMotte, III			
	7	5,565,322	10/15/96	Heller			
	8	5,580,859	12/03/96	Felgner et al.			
	9	5,583,108	12/10/96	Wei et al.			
	10	5,589,466	12/31/96	Felgner et al.			
	11	5,849,489	12/15/98	Heller			
	12	6,124,430	09/26/00	Mischak et al.			
	13	6,162,603	12/19/00	Heller			
	14	6,376,207	04/23/02	Mischak et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
	15	WO 84/03825	10/11/84	WIPO				
	16	WO 00/71576	11/30/00	WIPO				
	17	WO 01/44284	06/21/01	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	l ID	Document		
	18	Abdelhafiz, "Heart failure in older people: causes, diagnosis and treatment," Age Ageing, 2002, 31(1):29-36		
	19	Best et al., "Dendroaspis natriuretic peptide relaxes isolated human arteries and veins," <u>Cardiovas.</u> Res., 2002, 55:375-384		
	20	Burger and Burger, "BNP in decompensated heart failure: Diagnostic, prognostic and therapeutic potential," Curr. Opin. Investig. Drugs, 2001, 2(7):929-35		

Examiner Signature	Date Considered		
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Substitute Form PTO-1449 (Modified)	Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Application No. 10/561,014
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Shuchong Pan et al.	
		Filing Date December 16, 2005	Group Art Unit 1649

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
	21	Chaurand et al., "Peptide and Protein Identification by Matrix-Assisted Laser Desorption Ionization (MALDI) and MALDI-Post-Source Decay Time-of-Flight Mass Spectrometry," J. Am. Soc. Mass Spectrom., 1999, 10(2):91-103
	22	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,"  Monoclonal Antibodies and Cancer Therapy, 1985, Alan R. Liss, Inc., pp. 77-96
	23	Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens," <u>Proc. Natl. Acad. Sci. USA</u> , 1983, 80:2026-2030
	24	Cowie and Mendez, "BNP and Congestive Heart Failure," <u>Prog. Cardiovasc. Dis.</u> , 2002, 44(4):293-321
	25	Gevaert et al., "Protein identification based on matrix assisted laser desorption/ionization-post source decay-mass spectrometry," <u>Electrophoresis</u> , 2001, 22(9):1645-51
	26	Guatelli et al., "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication," Proc. Natl. Acad. Sci. USA, 1990, 87:1874-1878
	27	Huse et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science, 1989, 246:1275-1281
	28	Hyrup and Nielsen, "Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications," Bioorgan. Med. Chem., 1996, 4:5-23
	29	Köhler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, 1975, 256:495-497
	30	Kozbor and Roder, "The production of monoclonal antibodies from human lymphocytes,"  Immunology Today, 1983, 4:72-79
	31	Lewis, "PCR's Competitors Are Alive and Well and Moving Rapidly Towards Commercialization," Genetic Engineering News, 1992, 12(9):1-3
	32	Peacock, "The B-type natriuretic peptide assay: a rapid test for heart failure," Cleve. Clin. J. Med., 2002, 69(3):243-251
	33	Richards et al., "BNP in hormone-guided treatment of heart failure," <u>Trends Endocrinol. Metab.</u> , 2002, (5):151-155
	34	Sagnella, "Practical implications of current natriuretic peptide research," J. Renin. Angiotensin Aldosterone Syst., 2000, 1(4):304-315
	35	Ausubel et al. (eds.), Short Protocols in Molecular Biology, 1992, Chapters 8 and 11, Green Publishing Associates and John Wiley & Sons
	36	Summerton and Weller, "Morpholino Antisense Oligomers: Design, Preparation, and Properties," <u>Antisense Nucleic Acid Drug Dev.</u> , 1997, 7:187-195
	37	Tremblay et al., "Biochemistry and physiology of the natruiretic peptide receiptor guanylyl cyclases," Mol. Cell. Biochem., 2002, 230(1-2):31-47
	38	Walther et al., "Natriuretic peptide system in fetal heart and circulation," J. Hypertens., 2002, 20(5):786-791
-	39	Weiss, "Hot Prospect for New Gene Amplifier," Science, 1991, 254:1292-1293

Examiner Signature	Date Considered		
<u>'</u>			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with			

next communication to applicant.